Business context and reporting period
This is ReShape Lifesciences Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed April 8, 2022—not a quarterly report. The request metadata names Vyome Holdings, Inc., but the filing provided is for ReShape Lifesciences Inc. The company sells the Lap-Band system and offers virtual weight-management coaching and an online marketplace; its Obalon balloon product had not been reintroduced, while the ReShape Vest and Diabetes Bloc-Stim Neuromodulation remained in development. The June 2021 Obalon merger was accounted for as a reverse acquisition.
Key financial metrics
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $13.6 million | $11.3 million |
| Gross profit / margin | $8.3 million / 61.4% | $6.3 million / 55.4% |
| Operating loss | $56.5 million | $12.5 million |
| Net loss | $61.9 million | $21.6 million |
| Adjusted EBITDA (non-GAAP loss) | $10.6 million | $9.1 million |
| Net cash used in operating activities | $15.4 million | $8.6 million |
| Cash and cash equivalents at year-end | $22.8 million | $3.0 million |
| Debt at year-end | $0 | $13.3 million gross debt |
Net working capital was approximately $22.9 million at December 31, 2021. The company reported total liabilities of $8.2 million and stockholders’ equity of $46.1 million. Interest expense was $0.8 million; the company also recorded $2.8 million of warrant expense and a $2.1 million net loss on debt extinguishment. The independent auditor issued an unmodified opinion on the financial statements; the auditor was not engaged to audit internal control effectiveness.
Material changes versus 2020
- Revenue rose 20.4% to $13.6 million. U.S. revenue increased 24.4% to $10.3 million; Australia declined 4.3% to $1.0 million, while Europe increased 16.6% to $2.1 million. Management attributed growth mainly to fewer pandemic restrictions on elective procedures, greater obesity awareness and increased marketing. Fourth-quarter sales softened amid Delta and Omicron-related restrictions.
- Gross margin improved to 61.4% from 55.4%, which management attributed to higher volume, a greater share of domestic sales and manufacturing cost savings after transferring Lap-Band production from Costa Rica to a U.S. supplier.
- Operating expenses increased to $64.8 million from $18.7 million. The 2021 total included $28.8 million of impairment charges—$21.6 million for goodwill and $7.2 million for in-process research and development—and $12.8 million of stock-based compensation. General and administrative expense also included $2.3 million of merger-related professional fees. Sales and marketing expense rose 95% to $9.2 million; R&D fell 28% to $2.5 million, partly because Vest clinical work slowed during the pandemic.
- The June financing generated approximately $45.5 million gross proceeds from warrant exercises and new warrant issuance. The company used about $10.8 million to repay its credit agreement; outstanding debt was zero at year-end. Common shares outstanding rose to 17.8 million from 3.5 million at year-end 2020, and 6.95 million warrants remained outstanding at year-end 2021.
Outlook, commentary and risks
- Management expects operating losses and negative operating cash flows to continue in 2022 and for the foreseeable future. It stated that available capital should fund operations for at least one year from the financial statements’ issuance date, but also said additional capital will be required and may not be available on acceptable terms.
- Management expects sales and marketing expense to increase in 2022 as it continues the national consumer advertising campaign. It anticipated more reshape care revenue in 2022; the filing gives no numerical revenue or earnings guidance.
- Obalon had no revenue after the merger through year-end. Relaunch depends on restarting manufacturing, restoring supplier and regulatory capabilities, and market acceptance. The Vest trial and follow-up work were disrupted by COVID-19; timing for resuming enrollment and pursuing CE certification remained uncertain. Diabetes Bloc-Stim was preclinical.
- Key risks include continued cash burn and potential dilution; reliance on Lap-Band sales; product acceptance, reimbursement and supplier capacity; regulatory and clinical delays; competition; and COVID-19 effects on elective procedures. The company also disclosed two unaccrued fee disputes: Cowen claims $1.35 million plus interest and legal fees related to the Obalon merger; H.C. Wainwright claims a fee based on 8% of certain warrant-exercise proceeds. Outcomes and potential exposure were not clear.
- Two impairment charges were driven by lower market capitalization and, for the Vest-related IPR&D, delayed expected cash flows. Goodwill was fully impaired. The company reported effective disclosure controls and effective internal control over financial reporting as of year-end; the auditor did not provide an internal-control audit opinion.
Important facts for investors to verify
- Confirm the filing issuer and reporting period: this document is ReShape Lifesciences Inc.’s 2021 annual report, not a Vyome Holdings filing or a standalone Q4 report.
- Track cash burn, financing needs and runway against the company’s stated expectation of continued losses; assess the terms and dilution risk of any future capital raise.
- Monitor Lap-Band revenue, gross margin and the cost and effectiveness of the advertising campaign, as well as actual reshape care revenue.
- Verify progress on Obalon manufacturing and relaunch, Vest trial resumption and regulatory milestones, and Diabetes Bloc-Stim development.
- Review the two disputed advisor-fee claims, the $4.1 million of purchase commitments, and the potential for further impairment or other non-cash charges.